Prestige Biopharma Submitted Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar

2022年10月15日 13:44:31 来自: (0)参与

SINGAPORE -- (BUSINESS WIRE) --

Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, has submitted a request to the U.S. Food and Drug Administration (FDA) for a pre-submission meeting to discuss the company’s planned Biologics License Application (BLA) for its Herceptin Biosimilar, HD201(Tuznue®).

The Biosimilar Biological Product Development (BPD) Type 4 Meeting is to discuss the format and content of a BLA in advance of the final submission. The company will discuss the overall development program of HD201 with the FDA to identify potential filing and review issues. The meeting is expected to take place around November, and the BLA submission by the end of the year.

Prestige Biopharma’s HD201 is a proposed biosimilar to Roche’s Herceptin® (trastuzumab) to be prescribed for the treatment of human epidermal growth factor 2 (HER2) positive breast and metastatic gastric cancer. Trastuzumab targets HER2, which is overexpressed in some types of cancer cells and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.

Currently, a New Drug Submission (NDS) for HD201 is under review by Health Canada and a Marketing Authorisation Application (MAA) by the Korea Ministry of Food and Drug Safety. In addition to filing a new MAA to the European Medicines Agency (EMA), the company also plans to apply for authorisation in other advanced biosimilars markets such as UK, Australia, and Singapore.

Lisa Park, CEO of Prestige Biopharma, commented: “This Type 4 Meeting will be the final gate of BLA submission for HD201. In addition to the Bridging Study on biosimilarity of HD201 to US-Herceptin® and the Biosimilar Initial Advisory Meeting with FDA in 2019, we have been through a series of meetings with the FDA on each step of the development to prepare the launch of HD201 in US to help more patients in need. We will take this final step to thoroughly review and finalise the application for FDA’s approval.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20221013006097/en/

CONTACT:

Media Inquiries
Global Communications, Prestige Biopharma
www.prestigebiopharma.com
Yujin Suh
+65-6924-6535
info@prestigebio.com

相关新闻
本网网友:她有我保护
评论:虎落平阳被犬欺、落配凤凰不如鸡 。

淘宝网友:昔年°  /21c
评论:人生就像愤怒的小鸟,当你失败时,总有几只猪在笑。。。

其它网友:俄怎会放得下
评论:我以为你只是颓废,原来你已经报废了。

凤凰网友:羡慕嫉妒恨≈
评论:每次考完试,我都要安慰自己,没关系,重在参与。

搜狐网友:独白   song
评论:美国纽约一劫匪在抢劫银行时说了一句至理名言:“通通不许动,钱是国家的,命是自己的!”

腾讯网友:⒈朵死亡花°
评论:吃得苦中苦,才能开路虎;少年不努力,只能开夏利

猫扑网友:偏心   ■
评论:什么是兄弟?兄弟就是50年后你老了躺在床上,我问你喝水不?你摇头。吃水果不?你还是摇头。我再问:给你找个妞?你睁大眼睛,眼里闪着泪花。兄弟,扶我起来试试。。。

百度网友:Pawonx-爱离殇
评论:领“鲜”一步

天涯网友:Sunny°刺眼
评论:有些人,认真的让你心疼,有些人,欠扁的让你牙疼

天猫网友:Flowers 繁花
评论:泰坦尼克号选在2012上映是要告诉我们,作为屌丝,就算你搞到了船票,也是死路一条。

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin